Loading...
VERV logo

Verve Therapeutics, Inc.NasdaqGS:VERV Rapporto sulle azioni

Cap. di mercato US$991.5m
Prezzo delle azioni
US$11.13
US$15.11
26.3% sottovalutato sconto intrinseco
1Y48.8%
7D1.6%
1D
Valore del portafoglio
​
Vista

Verve Therapeutics, Inc.

Report azionario NasdaqGS:VERV

Capitalizzazione di mercato: US$991.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Verve Therapeutics (VERV) Panoramica del titolo

Verve Therapeutics, Inc. è una società in fase clinica che sviluppa farmaci per l'editing genico destinati ai pazienti per il trattamento delle malattie cardiovascolari negli Stati Uniti. Maggiori dettagli

VERV analisi fondamentale
Punteggio fiocco di neve
Valutazione0/6
Crescita futura0/6
Prestazioni passate0/6
Salute finanziaria6/6
Dividendi0/6

Analisi del rischio

Si prevede che gli utili diminuiranno in media di 15.7% all'anno per i prossimi 3 anni

Prezzo delle azioni altamente volatile negli ultimi 3 mesi rispetto al mercato US

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni


VERV Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Concorrenti di Verve Therapeutics, Inc.

Storia dei prezzi e prestazioni

Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Verve Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azioneUS$11.13
Massimo di 52 settimaneUS$11.41
Minimo di 52 settimaneUS$2.86
Beta2.24
Variazione di 1 mese-0.36%
Variazione a 3 mesi93.23%
Variazione di 1 anno48.80%
Variazione a 3 anni-59.60%
Variazione a 5 annin/a
Variazione dall'IPO-65.13%

Notizie e aggiornamenti recenti

Seeking Alpha • Jun 17

Verve Therapeutics' Lifeline: Eli Lilly's $1.3 Billion Bet On Cardiovascular Gene Therapy (Upgrade)

Summary Eli Lilly's $1.3B offer for Verve Therapeutics is a lifeline, providing a 70%+ premium and a solid exit for Verve investors. VERV struggled as a standalone due to tough gene therapy commercialization and competition from established cardiovascular treatments like statins and PCSK9 inhibitors. For LLY, the acquisition diversifies its pipeline and positions it for future innovation in chronic disease, despite high risk and uncertain payoff. The deal is mutually beneficial: Verve gets a strong exit, while Eli Lilly makes a speculative, forward-looking bet with its abundant cash reserves. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Jun 17

Verve Therapeutics' Lifeline: Eli Lilly's $1.3 Billion Bet On Cardiovascular Gene Therapy (Upgrade)

Summary Eli Lilly's $1.3B offer for Verve Therapeutics is a lifeline, providing a 70%+ premium and a solid exit for Verve investors. VERV struggled as a standalone due to tough gene therapy commercialization and competition from established cardiovascular treatments like statins and PCSK9 inhibitors. For LLY, the acquisition diversifies its pipeline and positions it for future innovation in chronic disease, despite high risk and uncertain payoff. The deal is mutually beneficial: Verve gets a strong exit, while Eli Lilly makes a speculative, forward-looking bet with its abundant cash reserves. Read the full article on Seeking Alpha
Articolo di analisi • May 28

Verve Therapeutics, Inc. (NASDAQ:VERV) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Unfortunately for some shareholders, the Verve Therapeutics, Inc. ( NASDAQ:VERV ) share price has dived 26% in the last...
Articolo di analisi • May 19

News Flash: Analysts Just Made An Incredible Upgrade To Their Verve Therapeutics, Inc. (NASDAQ:VERV) Forecasts

Verve Therapeutics, Inc. ( NASDAQ:VERV ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Apr 16

Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy'

Summary VERV’s VERVE-102 showed an impressive 69% LDL-C reduction in its early Phase 1b data. Also, LLY may opt into VERVE-102’s development later this year, which would help VERV by covering one-third of the R&D costs. Similarly, VERV’s pipeline includes VERVE-201 for HoFH and refractory hypercholesterolemia, as well as VERVE-301 in collaboration with Lilly. And from a valuation perspective, the shares are cheaper than the first time I covered it. All while making great progress with its pipeline. So, ultimately, I think VERV remains a high-risk, long-term play in gene editing. But its risk-reward profile now seems to justify a “Buy” rating. Read the full article on Seeking Alpha
Seeking Alpha • Mar 25

Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts

Summary Company received FDA IND clearance for VERVE-102 to treat HeFH, adding new trial sites in the United States. The switch to the Gal-NAc LNP delivery system aims to improve safety, avoiding clinical abnormalities observed with VERVE-101. Key upcoming catalysts include initial phase 1b Heart-2 data in Q2 2025, final dose-escalation data, and potential Eli Lilly opt-in for PCSK9 inhibitor program in the 2nd half of 2025. Atherosclerotic Cardiovascular Disease, in the 7 Major Markets, is expected to reach $30.6 billion by 2035. Read the full article on Seeking Alpha
Seeking Alpha • Feb 28

Verve Therapeutics: Key Data Catalysts, Major Share Price Volatility In Play In Q2

Summary Verve Therapeutics' stock remains a "Buy" despite recent setbacks, including the retirement of its Chief Medical Officer and the termination of a collaboration with Vertex. Verve's gene-editing programs aim to transform cardiovascular disease treatment by permanently lowering cholesterol through a one-time intravenous infusion, offering significant therapeutic and commercial potential. The upcoming data readout for Verve-102 in 2025 is crucial; success could attract Eli Lilly's partnership, while failure may question the entire base editing approach. Despite leadership changes and challenges, Verve's innovative approach and potential for groundbreaking treatments justify a high-risk, high-reward investment strategy. Read the full article on Seeking Alpha
Articolo di analisi • Dec 08

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Aug 30

Verve Therapeutics: An In Vivo Gene Editing 'Moon Shot' For Your Portfolio

Summary Verve Therapeutics aims to revolutionize cardiovascular disease treatment with single-course gene editing, despite facing significant challenges and setbacks in clinical trials. The company's lead assets, VERVE-101 and VERVE-102, target the PCSK9 gene to lower LDL-C levels, but safety issues have hindered progress. Verve-102, using a different delivery technology, is now the focus, with initial data expected in 1H25, presenting a crucial milestone for investors. Partnerships with Eli Lilly, Beam Therapeutics, and Vertex offer potential financial support and validation, but Verve remains a high-risk, high-reward investment. Read the full article on Seeking Alpha
Articolo di analisi • Aug 10

Earnings Release: Here's Why Analysts Cut Their Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target To US$25.78

As you might know, Verve Therapeutics, Inc. ( NASDAQ:VERV ) just kicked off its latest second-quarter results with some...
Articolo di analisi • Jul 12

We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Jun 13

Why Verve Therapeutics Deserves A Spot On Your Watchlist

Summary Verve Therapeutics focuses on gene editing technology for one-dose therapies to reduce lipid levels related to ASCVD. VERV's pipeline includes therapies targeting genes like PCSK9, ANGPTL3, and LPA to lower ASCVD risk. Verve's leading programs, VERVE-101 and VERVE-102, target heterozygous familial hypercholesterolemia (HeFH), with VERVE-101 in clinical trials and VERVE-102 in the IND-enabling stage. Financially, Verve has a strong cash position, with $606.3 million in liquidity and a cash runway of approximately 3.5 years. VERV's research is in the early stages, making it a speculative investment, but it is worth adding to a watchlist as research progresses. Read the full article on Seeking Alpha
Articolo di analisi • May 14

Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher

Verve Therapeutics, Inc. ( NASDAQ:VERV ) shareholders will have a reason to smile today, with the analysts making...
Articolo di analisi • May 12

The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts

As you might know, Verve Therapeutics, Inc. ( NASDAQ:VERV ) just kicked off its latest first-quarter results with some...
Seeking Alpha • Apr 03

Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause

Summary Enrollment paused in the Verve Therapeutics' phase 1b heart-1 study, using VERVE-101 for the treatment of patients with heterozygous familial hypercholesterolemia after a Grade 3 adverse event. Despite VERVE-101 setback, the ability to move forward with another PCSK9 inhibitor known as VERVE-102 where the phase 1b heart-2 study is expected to begin any day now in Q2 2024. VERVE-102 could be a major change in structure because it has two distinct features compared to its predecessor, which are a different ionizable lipid and the GalNAc delivery system. Partnership with Eli Lilly remains in place for now, despite VERVE-101 enrollment being paused. Read the full article on Seeking Alpha
Articolo di analisi • Feb 28

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Feb 13

Verve's Proof-Of-Concept Data Doesn't Inspire Confidence

Summary Verve Therapeutics aims to revolutionize cardiovascular disease treatment with gene therapy. Recent VERVE-101 data shows LDL-C reduction comparable to existing drugs but with serious adverse events in two patients, raising safety concerns. Verve's financials show a solid runway with ~$600 million in liquid assets after a recent capital infusion, but ongoing and future trials will demand substantial funding. Recommendation: Sell. Despite proof-of-concept and a one-time treatment appeal, safety concerns and competitive landscape challenge its long-term valuation. Read the full article on Seeking Alpha
Seeking Alpha • Jan 14

Vectoring In On Verve Therapeutics

Summary Verve Therapeutics aims to revolutionize treatment for cardiovascular disease through in vivo gene therapy using base editing technology. Their lead candidate, VERVE-101, has shown promising results in reducing LDL-C levels in preclinical studies. Verve has partnerships with Beam Therapeutics, Eli Lilly, and Vertex Pharmaceuticals, and analysts have a positive outlook on the company. A full investment analysis around Verve Therapeutics stock is presented in the paragraphs below. Read the full article on Seeking Alpha
Articolo di analisi • Jun 07

Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Articolo di analisi • Feb 24

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Nov 09

We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 20

Verve Therapeutics: Cathie Wood Adds To ARKK

Summary ARKG component added to flagship fund. Meaningful position would top 7% of outstanding shares. Company fits usual pattern with large losses and cash burn.

Rendimenti per gli azionisti

VERVUS BiotechsUS Mercato
7D1.6%-1.6%-0.8%
1Y48.8%34.4%27.1%

Ritorno vs Industria: VERV ha superato il US Biotechs che ha restituito 34.4 % nell'ultimo anno.

Rendimento vs Mercato: VERV ha superato il mercato US che ha restituito 27.1 % nell'ultimo anno.

Volatilità dei prezzi

Is VERV's price volatile compared to industry and market?
VERV volatility
VERV Average Weekly Movement24.9%
Biotechs Industry Average Movement11.0%
Market Average Movement7.2%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.2%

Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di VERV è stato volatile rispetto al mercato US.

Volatilità nel tempo: La volatilità settimanale di VERV è aumentata da 18% a 25% nell'ultimo anno.

Informazioni sull'azienda

FondatoI dipendentiAMMINISTRATORE DELEGATOSito web
2018274Sek Kathiresanwww.vervetx.com

Verve Therapeutics, Inc. è una società in fase clinica che sviluppa farmaci per l'editing genico destinati ai pazienti per il trattamento delle malattie cardiovascolari negli Stati Uniti. I prodotti candidati dell'azienda includono VERVE-101, che è in corso di valutazione nello studio Heart-1, uno studio clinico di Fase 1b in aperto, e le modifiche dei livelli di proteina PCSK9 e LDL-C nel sangue in pazienti affetti da ipercolesterolemia familiare eterozigote (HeFH); VERVE-102, che è in corso di valutazione nello studio Heart-2, uno studio clinico di Fase 1b in aperto in pazienti adulti con HeFH e/o malattie coronariche premature; VERVE-201, che ha come bersaglio ANGPTL3 e spegne in modo permanente il gene ANGPTL3 nel fegato; e VERVE-301, un candidato allo sviluppo che utilizza un nuovo approccio di editing genico in vivo per spegnere in modo permanente il gene LPA nel fegato e ridurre i livelli di Lp(a) nel sangue. L'azienda ha un accordo di collaborazione e licenza con Beam Therapeutics Inc.; un accordo di sviluppo e opzione con Acuitas Therapeutics, Inc.; un accordo di licenza per la tecnologia lipidica con Novartis Pharma AG e Eli Lilly and Company; e un accordo di licenza per Cas9 con The Broad Institute and the President and Fellows of Harvard College.

Verve Therapeutics, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Verve Therapeutics con la sua capitalizzazione di mercato?
VERV statistiche fondamentali
Capitalizzazione di mercatoUS$991.46m
Utili (TTM)-US$181.01m
Ricavi(TTM)US$59.61m
16.7x
Rapporto P/S
-5.5x
Rapporto P/E

VERV è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Utili e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
VERV Conto economico (TTM)
RicaviUS$59.61m
Costo del fatturatoUS$210.43m
Profitto lordo-US$150.82m
Altre speseUS$30.19m
Utili-US$181.01m

Ultimi utili riportati

Mar 31, 2025

Prossima data di guadagno

n/a

Utile per azione (EPS)-2.03
Margine lordo-252.99%
Margine di profitto netto-303.64%
Rapporto debito/patrimonio netto0%

Come si è comportato VERV nel lungo periodo?

Vedi performance storica e confronto

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2025/07/24 14:27
Prezzo dell'azione a fine giornata2025/07/24 00:00
Utili2025/03/31
Utili annuali2024/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Verve Therapeutics, Inc. è coperta da 4 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Andrea NewkirkGoldman Sachs
Andrea NewkirkGoldman Sachs
Mitchell KapoorH.C. Wainwright & Co.